NOVO NORDISK INC.

Novo post hoc analysis finds Wegovy® 2.4 mg was associated with improvements in liver markers in adults with MASH with liver scarring and a BMI less than 27 kg/m2, presented at The Liver Meeting® (AASLD) 2026

A post hoc analysis of adults with MASH and liver scarring with a BMI below 27 kg/m² found that measures of liver injury, fibrosis, and disease…